TopMD Analysis

Pathway-based biomarkers for disease phenotype mapping

Identify disease phenotypes in cancer patients using pathway topology; Map molecular phenotypes in rare diseases with low biomarker variability; Characterize disease modulation in COVID-19 patient cohorts; Discover robust biomarkers for drug development pipelines; Analyze gene expression in longitudinal patient studies; Validate pathway biomarkers in clinical trials; Enable precision medicine in personalized treatment plans

Participates in EU-funded DRAGON consortium for COVID-19 diagnostics; Focuses on molecular phenotyping for drug development and patient treatment; Offers pathway-based biomarker discovery using topological data analysis